Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Research & Development (2024 - 2026)

Prelude Therapeutics' Research & Development history spans 3 years, with the latest figure at $13.6 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 52.8% to $13.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $79.1 million, a 33.77% decrease, with the full-year FY2025 number at $94.3 million, down 20.08% from a year prior.
  • Research & Development hit $13.6 million in Q1 2026 for Prelude Therapeutics, down from $18.0 million in the prior quarter.
  • Over the last five years, Research & Development for PRLD hit a ceiling of $31.6 million in Q4 2024 and a floor of $13.6 million in Q1 2026.
  • Historically, Research & Development has averaged $25.1 million across 3 years, with a median of $27.4 million in 2024.
  • Biggest five-year swings in Research & Development: rose 5.13% in 2025 and later plummeted 52.8% in 2026.
  • Tracing PRLD's Research & Development over 3 years: stood at $31.6 million in 2024, then plummeted by 43.1% to $18.0 million in 2025, then dropped by 24.41% to $13.6 million in 2026.
  • Business Quant data shows Research & Development for PRLD at $13.6 million in Q1 2026, $18.0 million in Q4 2025, and $21.7 million in Q3 2025.